Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

April 30, 2019

Study Completion Date

May 9, 2023

Conditions
X-linked Retinoschisis
Interventions
BIOLOGICAL

rAAV2tYF-CB-hRS1

adeno-associated virus vector expressing retinoschisin

Trial Locations (9)

21287

The Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore

27710

Duke Eye Center, Duke University Medical Center, Durham

33136

University of Miami - Miller School of Medicine Bascom Palmer Eye Institute, Miami

48105

University of Michigan Kellogg Eye Center, Ann Arbor

75231

Retina Foundation of the Southwest, Dallas

77030

Baylor College of Medicine, Alkek Eye Center, Houston

94143

University of California San Francisco, Dept. of Ophthalmology, San Francisco

97239

Casey Eye Institute, Oregon Health and Sciences University, Portland

02114

Massachusetts Eye and Ear Infirmary, Boston

Sponsors
All Listed Sponsors
lead

Beacon Therapeutics

INDUSTRY